Patents by Inventor Glenn Noronha
Glenn Noronha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080027070Abstract: Compounds having the general structure (A) are provided. The compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, Vegfr and various other specific receptor and non-receptor kinases.Type: ApplicationFiled: July 2, 2007Publication date: January 31, 2008Applicant: TargeGen, Inc.Inventors: Glenn Noronha, Jianguo Cao, Colleen Gritzen, Chi Ching Mak, Andrew McPherson, Ved Pathak, Joel Renick, Richard Soll, Binqi Zeng, Elena Dneprovskaia
-
Publication number: 20070259876Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as uveitis, retinopathies or macular degeneration, macular edema or other vitreoretinal diseases, inflammatory diseases such as autoimmune diseases, vascular leakage syndrome, edema, or diseases involving leukocyte activation, transplant rejection, respiratory diseases such as asthma, adult or acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, and the like.Type: ApplicationFiled: April 25, 2007Publication date: November 8, 2007Applicant: TargeGen, Inc.Inventors: John Doukas, Chi Mak, Elena Dneprovskaia, Glenn Noronha
-
Publication number: 20070259904Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.Type: ApplicationFiled: April 26, 2007Publication date: November 8, 2007Applicant: TargeGen, Inc.Inventors: Glenn Noronha, Chi Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved Pathak, Daniel Lohse, John Hood, Richard Soll
-
Publication number: 20070208019Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: ApplicationFiled: January 11, 2007Publication date: September 6, 2007Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Publication number: 20070191405Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.Type: ApplicationFiled: October 26, 2006Publication date: August 16, 2007Applicant: TargeGen, Inc.Inventors: Glenn Noronha, Chi Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved Pathak, Daniel Lohse, John Hood, Richard Soll
-
Publication number: 20070161645Abstract: A compound is provided, having the general structure (A): wherein A is an aryl or heteroaryl group, Y is a hydrophbic linking moiety, and L is a substitutent. The compound (A) can be used for treatment of various angiogenic-associated or hematologic disorders, such as myeloproliferative disorders in patients who do not respond to kinase-inhibition therapy that comprises administering currently used medications.Type: ApplicationFiled: October 31, 2006Publication date: July 12, 2007Applicant: TargeGen, Inc.Inventors: Glenn Noronha, Jianguo Cao, Binqi Zeng, Chi Mak, Andrew McPherson, Joel Renick, Ved Pathak, Chun Chow, Moorthy Palanki, Richard Soll, Daniel Lohse, John Hood, Elena Dneprovskaia
-
Publication number: 20070149508Abstract: A compound is provided, having the general structure (A): wherein A is an (un)substituted aryl or (un)substituted heteroaryl moiety, G is N, CH, or CR, R is an unsubstituted or substituted lower alkyl, Y is a hydrophobic linking moiety, and L is a substitutent as defined. The compound (A) can be used for treatment of various angiogenic and hematological-associated disorders, such as myeloproliferative disorder in patients who do not respond to kinase-inhibition therapy that comprises administering approved medications.Type: ApplicationFiled: October 31, 2006Publication date: June 28, 2007Applicant: TargeGen, Inc.Inventors: Glenn Noronha, Jianguo Cao, Binqi Zeng, Chi Mak, Andrew McPherson, Joel Renick, Ved Pathak, Chun Chow, Moorthy Palanki, Richard Soll, Daniel Lohse, John Hood, Elena Dneprovskaia
-
Patent number: 7208493Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: GrantFiled: October 2, 2003Date of Patent: April 24, 2007Assignee: TargeGen, Inc.Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Publication number: 20060247250Abstract: The invention provides pyrimidine compounds having formula A. The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, and various other specific receptor and non-receptor kinases.Type: ApplicationFiled: March 15, 2006Publication date: November 2, 2006Applicant: TargeGen, Inc.Inventors: Jianguo Cao, Richard Soll, Glenn Noronha, Kathy Barrett, Colleen Gritzen, John Hood, Chi Mak, Andrew McPherson, Ved Pathak, Joel Renick, Ute Splittgerber, Binqi Zeng
-
Patent number: 7045361Abstract: Fluorescent biosensor molecules, fluorescent biosensors and systems, as well as methods of making and using these biosensor molecules and systems are described. These biosensor molecules address the problem of obtaining fluorescence emission at wavelengths greater than about 500 nm. Biosensor molecules generally include an (1) an acridine-based fluorophore, (2) a linker moiety and (3) a boronate substrate recognition/binding moiety, which binds polyhydroxylate analytes, such as glucose. These biosensor molecules further include a “switch” element that is drawn from the electronic interactions among these submolecular components. This fluorescent switch is generally “off” in the absence of bound polyhydroxylate analyte and is generally “on” in the presence of bound polyhydroxylate analyte. Thus, the reversible binding of a polyhydroxylate analyte essentially turns the fluorescent switch “on” and “off”.Type: GrantFiled: September 12, 2001Date of Patent: May 16, 2006Assignee: Medtronic MiniMed, Inc.Inventors: Aaron M. Heiss, Joseph C. Walsh, David J. Vachon, Glenn Noronha, Jonathan Reilly, Bill C. Ponder, William P. Van Antwerp
-
Publication number: 20050282814Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: ApplicationFiled: April 13, 2005Publication date: December 22, 2005Applicant: TargeGen, Inc.Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Publication number: 20050245524Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.Type: ApplicationFiled: April 7, 2005Publication date: November 3, 2005Applicant: TargeGen, Inc.Inventors: Glenn Noronha, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Xianchang Gong, John Hood, Chi Mak, Andrew McPherson, Ved Pathak, Joel Renick, Richard Soll, Ute Splittgerber, Wolfgang Wrasdilo, Ningning Zhao, Elena Dneprovskaia
-
Publication number: 20050191761Abstract: Fluorescent biosensor molecules, fluorescent biosensors and systems, as well as methods of making and using these biosensor molecules and systems are described. These biosensor molecules address the problem of obtaining fluorescence emission at wavelengths greater than about 500 nm. Biosensor molecules generally include an (1) an acridine-based fluorophore, (2) a linker moiety and (3) a boronate substrate recognition/binding moiety, which binds polyhydroxylate analytes, such as glucose. These biosensor molecules further include a “switch” element that is drawn from the electronic interactions among these submolecular components. This fluorescent switch is generally “off” in the absence of bound polyhydroxylate analyte and is generally “on” in the presence of bound polyhydroxylate analyte. Thus, the reversible binding of a polyhydroxylate analyte essentially turns the fluorescent switch “on” and “off”.Type: ApplicationFiled: September 12, 2001Publication date: September 1, 2005Inventors: Aaron Heiss, Joseph Walsh, David Vachon, Glenn Noronha, Jonathan Reilly, Bill Ponder, William Van Antwerp
-
Patent number: 6927246Abstract: Improved polymer matrices which incorporate fluorescent biosensor molecules as well as methods of making and using these polymer matrices are described. Such matrices can be used in fluorescent biosensors and biosensor systems, including those which are used in the detection of polyhydroxylated analytes such as glucose. The properties of the polymer matrices of the invention renders biosensors utilizing such matrices particularly well-suited for detecting and measuring in-vivo glucose concentrations.Type: GrantFiled: February 14, 2002Date of Patent: August 9, 2005Assignee: Medtronic MiniMed, Inc.Inventors: Glenn Noronha, Jonathan Reilly, Joseph C. Walsh, Brooks Cochran, Aaron M. Heiss, Bill C. Ponder, David J. Vachon
-
Publication number: 20040167198Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: ApplicationFiled: October 2, 2003Publication date: August 26, 2004Applicant: TargeGen, Inc.Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Patent number: 6766183Abstract: Fluorescent biosensor molecules, fluorescent biosensors and systems, as well as methods of making and using these biosensor molecules and systems are described. Embodiments of these biosensor molecules exhibit fluorescence emission at wavelengths greater than about 650 nm. Typical biosensor molecules include a fluorophore that includes an iminium ion, a linker moiety that includes a group that is an anilinic type of relationship to the fluorophore and a boronate substrate recognition/binding moiety, which binds glucose. The fluorescence molecules modulated by the presence or absence of polyhydroxylated analytes such as glucose. This property of these molecules of the invention, as well as their ability to emit fluorescent light at greater than about 650 nm, renders these biosensor molecules particularly well-suited for detecting and measuring in-vivo glucose concentrations.Type: GrantFiled: December 28, 2001Date of Patent: July 20, 2004Assignees: Medtronic MiniMed, Inc., The Regents of the University of CaliforniaInventors: Joseph C. Walsh, Aaron M. Heiss, Glenn Noronha, David J. Vachon, Stephen M. Lane, Joe H. Satcher, Jr., Thomas A. Peyser, William Peter Van Antwerp, John Joseph Mastrototaro
-
Publication number: 20040074785Abstract: Embodiments of the invention provide analyte sensors having stabilized coating compositions and methods for making such sensors. Illustrative embodiments include electrochemical glucose sensors having stabilized glucose oxidase coatings that are generated for example, via spin coating processes.Type: ApplicationFiled: October 18, 2002Publication date: April 22, 2004Inventors: James D. Holker, John J. Mastrototaro, Glenn Noronha, Rajiv Shah, Yanan Zhang, Udo Hoss, Kevin D. Branch
-
Publication number: 20020197724Abstract: Improved polymer matrices which incorporate fluorescent biosensor molecules as well as methods of making and using these polymer matrices are described. Such matrices can be used in fluorescent biosensors and biosensor systems, including those which are used in the detection of polyhydroxylated analytes such as glucose. The properties of the polymer matrices of the invention renders biosensors utilizing such matrices particularly well-suited for detecting and measuring in-vivo glucose concentrations.Type: ApplicationFiled: February 14, 2002Publication date: December 26, 2002Inventors: Glenn Noronha, Jonathan Reilly, Joseph C. Walsh, Brooks Cochran, Aaron M. Heiss, Bill C. Ponder, David J. Vachon
-
Publication number: 20020193672Abstract: Fluorescent biosensor molecules, fluorescent biosensors and systems, as well as methods of making and using these biosensor molecules and systems are described. Embodiments of these biosensor molecules exhibit fluorescence emission at wavelengths greater than about 650 nm. Typical biosensor molecules include a fluorophore that includes an iminium ion, a linker moiety that includes a group that is an anilinic type of relationship to the fluorophore and a boronate substrate recognition/binding moiety, which binds glucose. The fluorescence molecules modulated by the presence or absence of polyhydroxylated analytes such as glucose. This property of these molecules of the invention, as well as their ability to emit fluorescent light at greater than about 650 nm, renders these biosensor molecules particularly well-suited for detecting and measuring in-vivo glucose concentrations.Type: ApplicationFiled: December 28, 2001Publication date: December 19, 2002Inventors: Joseph C. Walsh, Aaron M. Heiss, Glenn Noronha, David J. Vachon, Stephen M. Lane, Joe H. Satcher, Thomas A. Peyser, William Peter Van Antwerp, John Joseph Mastrototaro